Solid tumors resist CAR-T therapy through physical barriers, antigen heterogeneity, and an immunosuppressive microenvironment. Researchers have developed multiple engineering and clinical strategies to enable CAR-T cells to traffic to tumors, persist, and mediate cytotoxicity despite these obstacles. Evidence and guiding concepts have been articulated by leading investigators such as Carl H. June at the University of Pennsylvania and Michel Sadelain at Memorial Sloan Kettering Cancer Center, who emphasize design features and combination approaches to improve efficacy.
Physical and trafficking barriers
Dense extracellular matrix and abnormal vasculature limit CAR-T infiltration. Strategies to address this include coexpressing chemokine receptors that match tumor chemokines, and expressing enzymes such as heparanase to remodel the matrix. Regional delivery of CAR-T cells directly into the tumor or cavity can bypass systemic trafficking limits. Steven A. Rosenberg at the National Cancer Institute has long highlighted the importance of local delivery and tumor-infiltrating lymphocyte approaches for solid tumor access, demonstrating that proximity and persistence matter for anti-tumor activity. Regional approaches may be more feasible for accessible tumors such as glioblastoma or hepatic metastases and raise different logistical and cultural considerations than systemic infusion.Overcoming immunosuppression and heterogeneity
The tumor microenvironment suppresses T cells through checkpoint ligands, suppressive cells, and inhibitory cytokines. Combining CAR-T cells with systemic checkpoint inhibitors leverages the work of James P. Allison at the University of Texas MD Anderson Cancer Center on CTLA-4 blockade and can relieve inhibitory signaling. Genetic modifications that produce checkpoint resistance in CAR-T cells include PD-1 dominant-negative receptors or PD-1 gene disruption. Another approach is armored CARs that secrete cytokines such as IL-12 or IL-18 to reprogram local myeloid cells and enhance effector function, an idea advanced in translational immunology literature by groups including Michel Sadelain. To address antigen loss and heterogeneity, designers use multi-targeting constructs such as tandem CARs or synthetic Notch circuits that require combinatorial antigen recognition for activation, reducing escape.These strategies carry consequences in safety, manufacturing complexity, and access. Cytokine secretion and enhanced persistence increase the risk of systemic inflammation, requiring careful clinical management. Engineering complexity raises production costs and regulatory hurdles, which can exacerbate geographic disparities in access to advanced therapies. Balancing potency with safety and equitable delivery remains central as CAR-T approaches for solid tumors move from preclinical promise to clinical reality.